BioCardia Launches Innovative Morph DNA Steerable Introducer Family
BioCardia, Inc., a leader in cell-derived therapeutics for cardiovascular and pulmonary diseases, recently announced the commercial availability of its new Morph DNA steerable introducer product family. This innovative line is designed to enhance control and efficacy in biotherapeutic delivery for clinical applications.
CEO Peter Altman, PhD, expressed enthusiasm regarding the product’s potential, stating, "Our team is exploring an initial sales pipeline organically. We aim to showcase the benefits of the Morph DNA family to physicians, especially for vascular system procedures." This statement underscores the company’s commitment to presenting the advantages of its products without immediate reliance on a direct sales force or third-party partners.
Focus on Clinical Trials and Innovations
In addition to the introduction of the Morph DNA product family, BioCardia remains dedicated to its CardiAMP Heart Failure clinical trials. These trials are examining the efficacy of its investigational FDA-designated breakthrough therapy for ischemic heart failure. BioCardia anticipates sharing final findings from the CardiAMP Heart Failure I Trial by early next year, while the CardiAMP Heart Failure II Trial is actively enrolling patients across several prestigious centers.
Understanding the Morph DNA Steerable Introducer
The Morph DNA steerable introducer represents a significant advancement in therapeutic delivery devices. Engineered for enhanced maneuverability within the heart, this product family boasts bidirectional steering, an ergonomic actuation mechanism, and an adjustable brake for precise control. Its design features a swiveling side port within a hemostasis valve, which effectively addresses tangling issues commonly encountered in such procedures.
What sets the Morph DNA apart is its unique tensioning system. These elements, configured to rotate around the catheter shaft, facilitate consistent performance in any desired direction. The innovative design that draws parallels to a DNA double helix ensures smooth navigation and reduces mechanical 'whip', enhancing both user experience and patient safety.
Professional Resources and Information
For healthcare professionals interested in the Morph DNA steerable introducer, BioCardia provides a product brochure on its website. This document outlines the various model numbers and sizes available, ensuring that medical practitioners can find the right solution for their specific needs.
About BioCardia
Headquartered in Sunnyvale, California, BioCardia, Inc. is at the forefront of developing cellular and cell-derived therapeutics aimed at treating critical cardiovascular and pulmonary diseases. The company’s platforms, including CardiAMP and CardiALLO cell therapies, are supported by its Helix biotherapeutic delivery system and Morph vascular navigation technology, with various products in clinical development stages.
Frequently Asked Questions
What is the Morph DNA product family?
The Morph DNA product family is a series of steerable introducers designed to enhance the control of biotherapeutic delivery in clinical procedures.
How does BioCardia plan to market the Morph DNA products?
BioCardia is developing an organic sales pipeline without the immediate use of a direct sales force or third-party partners, focusing on demonstrating the products to physicians.
What are the key features of the Morph DNA Steerable Introducer?
Key features include bidirectional steering, ergonomic actuation, an adjustable brake for fine control, and a unique tensioning system for improved navigation.
Where can I find more information about BioCardia's clinical trials?
Additional information on BioCardia's clinical trials, including the CardiAMP Heart Failure I and II Trials, can be accessed on their official website.
Is the Morph DNA design patented or proprietary?
Yes, the Morph DNA design incorporates proprietary technology aimed at increasing the effectiveness of vascular procedures.
